CompletedNCT05741528
What is this study about?Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AnaheimSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT05304767
Official study titleAn Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixSchizophreniaMedication studyAges 18–65
- Countries
- United States, Bulgaria, Japan, + 1 other
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
CompletedNCT04659174
Official study titleAn Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–65
- Countries
- United States, Ukraine
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
UnknownNCT05870722
Official study titlePinpointing the Factors Affecting Clinical Study Experiences of Schizophrenia Patients
Current recruitment status is unconfirmed.
Location not clearly listedSchizophreniaObservational studyAges 18+
- Countries
- Sponsor
- Power Life Sciences Inc.
CompletedNCT00448630
Official study titleA MULTI-CENTER, NON-INVASIVE OBSERVATIONAL STUDY OF METABOLIC SYNDROME PARAMETERS IN SCHIZOPHRENIC PATIENTS USING ATYPICAL ANTIPSYCHOTICS
This study has finished and is no longer accepting participants.
Multiple locations, including KurttepeSchizophreniaObservational studyAges 18–55
- Countries
- Türkiye
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT00161044
Official study titleAn Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
This study has finished and is no longer accepting participants.
In CatonsvilleSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT04820309
Official study titleAn Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
TerminatedNCT05643170
Official study titleA Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
This study ended early.
Multiple locations, including AtlantaSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
CompletedNCT06315283
Official study titleA 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Los AlamitosSchizophreniaMedication studyAges 18–64
- Countries
- United States, United Kingdom, Croatia, + 1 other
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
UnknownNCT06351514
Official study titleAn Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Current recruitment status is unconfirmed.
In SingaporeSchizophreniaDevice studyAges 21–65
- Countries
- Singapore
- Sponsor
- Institute of Mental Health, Singapore
CompletedNCT01514682
Official study titleAnti-Inflammatory Combination Therapy for the Treatment of Schizophrenia
This study has finished and is no longer accepting participants.
In BaltimoreSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT01689181
Official study titleL'apathie Dans La Schizophrénie: Étude Neuropsychologique Et Anatomique
This study has finished and is no longer accepting participants.
In ParisSchizophreniaObservational studyAges 20–55
- Countries
- France
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
